UniQure NV (NASDAQ: QURE) just staged one of biotech's wildest rides of the year, soaring 248% in a single session after unveiling successful trial results for its experimental Huntington's disease gene therapy. Indeed, the stock reached a 5-year high, marking its best session ever. But if you think the move was a one-off sugar high, Wall Street begs to differ.Track QURE stock here.Read Also: uniQure Stock Jumps On Positive News, But Risks RemainAnalysts Flip Bullish, Targets Race HigherThe clinical data di ...